Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.

导出原文传递

翻译打印收藏纠错

作者： Charles L,Bennett ^[1] ; Martin W,Schoen ^[2] ; Shamia,Hoque ^[3] ; Bartlett J,Witherspoon ^[4] ; David M,Aboulafia ^[5] ; Catherine S,Hwang ^[5] ; Paul,Ray ^[4] ; Paul R,Yarnold ^[4] ; Brian K,Chen ^[6] ; Benjamin,Schooley ^[7] ; Matthew A,Taylor ^[8] ; Michael D,Wyatt ^[4] ; William J,Hrushesky ^[4] ; Y Tony,Yang ^[9]

作者单位： College of Pharmacy, University of South Carolina, Columbia, SC, USA; WJB Dorn VA Medical Center, Columbia, SC, USA; Department of Comparative Medicine and Evidence Based Medicine, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: bennettc@cop.sc.edu. ^[1] Saint Louis University School of Medicine, Saint Louis, MO, USA; John Cochran VA Medical Center, Saint Louis, MO, USA. ^[2] College of Engineering and Computing, University of South Carolina, Columbia, SC, USA; WJB Dorn VA Medical Center, Columbia, SC, USA. ^[3] College of Pharmacy, University of South Carolina, Columbia, SC, USA. ^[4] Virginia Mason Medical Center, Seattle, WA, USA. ^[5] The Arnold School of Public Health, University of South Carolina, Columbia, SC, USA; WJB Dorn VA Medical Center, Columbia, SC, USA. ^[6] College of Engineering and Computing, University of South Carolina, Columbia, SC, USA. ^[7] School of Medicine, University of South Carolina, Columbia, SC, USA. ^[8] School of Nursing and Milken Institute School of Public Health, George Washington University, Washington, DC, USA. ^[9]